NO20070049L - Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese - Google Patents

Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese

Info

Publication number
NO20070049L
NO20070049L NO20070049A NO20070049A NO20070049L NO 20070049 L NO20070049 L NO 20070049L NO 20070049 A NO20070049 A NO 20070049A NO 20070049 A NO20070049 A NO 20070049A NO 20070049 L NO20070049 L NO 20070049L
Authority
NO
Norway
Prior art keywords
disorders
angiogenesis
treatment
derivatives useful
pyrrolotriazine derivatives
Prior art date
Application number
NO20070049A
Other languages
English (en)
Norwegian (no)
Inventor
Harold Clinton Eugene Kluender
Julie A Dixon
Catherine Brennan
Karl Miranda
Brent Chandler
Barton Phillips
Jianmei Fan
Michael Brands
Andrea Mcclure
Benjamin Jones
Wenlang Fu
Donald Bierer
Steven Magnuson
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070049(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of NO20070049L publication Critical patent/NO20070049L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20070049A 2004-06-03 2007-01-03 Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese NO20070049L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57665204P 2004-06-03 2004-06-03
US62653104P 2004-11-09 2004-11-09
PCT/US2005/019472 WO2005121147A1 (en) 2004-06-03 2005-06-03 Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Publications (1)

Publication Number Publication Date
NO20070049L true NO20070049L (no) 2007-01-30

Family

ID=34971944

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070049A NO20070049L (no) 2004-06-03 2007-01-03 Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese

Country Status (30)

Country Link
US (3) US7563791B2 (es)
EP (1) EP1765823B1 (es)
JP (1) JP4958772B2 (es)
KR (1) KR101235602B1 (es)
CN (1) CN1993361B (es)
AR (1) AR049138A1 (es)
AT (1) ATE462708T1 (es)
AU (1) AU2005252217B2 (es)
BR (1) BRPI0510848A (es)
CA (1) CA2569396C (es)
DE (1) DE602005020293D1 (es)
EC (1) ECSP067043A (es)
ES (1) ES2342722T3 (es)
GT (1) GT200500137A (es)
HN (1) HN2005000255A (es)
IL (1) IL179264A0 (es)
MA (1) MA28689B1 (es)
MX (1) MX279139B (es)
MY (1) MY145077A (es)
NO (1) NO20070049L (es)
NZ (1) NZ551742A (es)
PE (1) PE20060243A1 (es)
PH (1) PH12006502386B1 (es)
RU (1) RU2401269C2 (es)
SG (1) SG127661A1 (es)
SV (1) SV2006002134A (es)
TW (1) TW200608979A (es)
UY (1) UY28931A1 (es)
WO (1) WO2005121147A1 (es)
ZA (1) ZA200700011B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
BRPI0620408B8 (pt) 2005-12-21 2021-05-25 Novartis Ag derivados de pirimidinil aril uréia sendo inibidores de fgf, seus usos, e preparação farmacêutica
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
US7912582B1 (en) * 2007-05-03 2011-03-22 Innovation Associates, Inc. Robotic prescription filling system
EP2195286A2 (en) * 2007-09-10 2010-06-16 Cipla Limited Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
CA2700489A1 (en) 2007-09-25 2009-04-02 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
CA2877474A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
PE20140570A1 (es) 2011-07-01 2014-04-28 Bayer Ip Gmbh Pirrolotriazinas sustituidas con hidroximetilarilo y sus usos
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
WO2013087647A1 (en) 2011-12-15 2013-06-20 Bayer Intellectual Property Gmbh Substituted benzothienyl - pyrrolotriazines and uses thereof in the treatment cancer
EP2817311B1 (en) 2012-02-23 2016-04-06 Bayer Intellectual Property GmbH Substituted benzothienyl-pyrrolotriazines and uses thereof
KR102420322B1 (ko) * 2014-06-17 2022-07-13 키에시 파르마슈티시 엣스. 피. 에이. 포스포이노시타이드 3-키나아제 억제제로서 인돌리진 유도체
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
CA3016161A1 (en) 2016-03-03 2017-09-08 Cornell University Small molecule ire1-alpha inhibitors
MD3436461T2 (ro) 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物
SI3687996T1 (sl) 2017-09-27 2022-04-29 Incyte Corporation Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM
MD3813800T2 (ro) 2018-06-29 2025-10-31 Incyte Corp Formulări de inhibitor al AXL/MER
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
US10829493B2 (en) 2019-04-12 2020-11-10 Blueprint Medicines Corporation Compositions and methods for treating KIT- and PDGFRA-mediated diseases
AU2020274083B9 (en) * 2019-05-13 2025-05-01 D.E. Shaw Research, Llc FGFR inhibitors and methods of use thereof
KR102781651B1 (ko) * 2019-09-26 2025-03-18 센젠 타겟알엑스, 아이엔씨. 치환된 방향족 융합 고리 유도체, 및 이를 포함하는 조성물, 및 이의 용도
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
WO2022007921A1 (zh) * 2020-07-10 2022-01-13 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途
TW202233625A (zh) 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2097384C1 (ru) * 1989-10-31 1997-11-27 Биокрист Фармасьютикалз Инк. Производные 2-амино-7-(chr2r3)-3н,5н-пирроло[3,2-d]-пиримидин-4-она, способы их получения и способ селективного ингибирования пролиферации т-лимфоцитов млекопитающего и не оказывающий воздействия на b-лимфоциты
DE60026297T2 (de) * 1999-05-21 2006-11-02 Bristol-Myers Squibb Co. Pyrrolotriazin kinasehemmer
YU37903A (sh) * 2000-11-17 2006-05-25 Bristol-Myers Squibb Company POSTUPCI LEČENJA STANJA POVEZANIH SA p38 KINAZOM I JEDINJENJA PIROLOTRIAZINA KOJA SE KORISTE KAO INHIBITORI KINAZE
WO2004013145A1 (en) * 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2005061519A1 (en) 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
KR101461680B1 (ko) * 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
CA2700489A1 (en) * 2007-09-25 2009-04-02 Bayer Healthcare Llc Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase

Also Published As

Publication number Publication date
CA2569396C (en) 2011-12-20
SV2006002134A (es) 2006-10-04
AU2005252217B2 (en) 2011-05-12
CA2569396A1 (en) 2005-12-22
SG127661A1 (en) 2007-01-30
KR101235602B1 (ko) 2013-02-21
MX279139B (es) 2010-09-21
ATE462708T1 (de) 2010-04-15
ES2342722T3 (es) 2010-07-13
US7563791B2 (en) 2009-07-21
DE602005020293D1 (de) 2010-05-12
EP1765823B1 (en) 2010-03-31
ZA200700011B (en) 2008-11-26
JP2008501703A (ja) 2008-01-24
EP1765823A1 (en) 2007-03-28
TW200608979A (en) 2006-03-16
MY145077A (en) 2011-12-15
IL179264A0 (en) 2007-03-08
KR20070035028A (ko) 2007-03-29
CN1993361A (zh) 2007-07-04
HK1109141A1 (en) 2008-05-30
PH12006502386B1 (en) 2010-12-23
WO2005121147A1 (en) 2005-12-22
AR049138A1 (es) 2006-06-28
RU2401269C2 (ru) 2010-10-10
MA28689B1 (fr) 2007-06-01
CN1993361B (zh) 2010-05-26
PE20060243A1 (es) 2006-04-21
US20130225809A1 (en) 2013-08-29
UY28931A1 (es) 2005-12-30
GT200500137A (es) 2006-05-18
AU2005252217A1 (en) 2005-12-22
US8338595B2 (en) 2012-12-25
RU2006147237A (ru) 2008-07-20
US20100075958A1 (en) 2010-03-25
HN2005000255A (es) 2010-09-17
MXPA06013457A (es) 2007-03-01
BRPI0510848A (pt) 2007-11-27
US20070208013A1 (en) 2007-09-06
NZ551742A (en) 2010-08-27
ECSP067043A (es) 2006-12-29
JP4958772B2 (ja) 2012-06-20

Similar Documents

Publication Publication Date Title
NO20070049L (no) Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ECSP055783A (es) Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
NO20072223L (no) Glykogenfosforylaseinhibitor forbindelser med farmsoytiske preparater av disse
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20052380L (no) Beta-amino-heterosykliske dipeptidylpeptidaseinhibitorer for behandling og forhindring av diabetes
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
WO2007070434A3 (en) Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
DE60330485D1 (de) Zur behandlung von diabetes
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
WO2006058064A3 (en) Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
TW200630096A (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
WO2004074243A3 (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE449604T1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
SE0403006D0 (sv) New compounds
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20064732L (no) Alfa-aminoamidderivater nyttige i behandlingen av urolige bein-syndromet og additive lidelser
NO20080354L (no) Benzofuranylderivater som 5-HT6-reseptorinhibitorer
GB0407025D0 (en) Novel compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application